PG 116800

Drug Profile

PG 116800

Alternative Names: PG 530742

Latest Information Update: 06 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Class Heart failure therapies; Hydroxamic acids
  • Mechanism of Action Metalloprotease inhibitors; Metalloprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Osteoarthritis

Most Recent Events

  • 18 Apr 2005 Data presented at the 54th Annual Scientific Sessions of the American College of Cardiology (ACC-2005) have been added to the Adverse events and Heart Failure pharmacodynamics sections
  • 17 Mar 2004 Data presented at the 53rd Annual Scientific Sessions of the American College of Cardiology (ACC-2004) have been added to the Heart Failure pharmacodynamics section
  • 31 Aug 2003 Phase-II clinical trials in Heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top